menu
    • menu
    [{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 neutralizing antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"HiFiBiO Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"HFB301001","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Coronavirus Immunotherapy Consortium","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Mono & Bi-specific antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Coronavirus Immunotherapy Consortium","highestDevelopmentStatusID":"4","companyTruncated":"HiFiBiO Therapeutics \/ Coronavirus Immunotherapy Consortium"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"HFB30132A","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Anti-AML specific antibodies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Kite","highestDevelopmentStatusID":"2","companyTruncated":"HiFiBiO Therapeutics \/ Kite"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"ABL Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"HFB30132A","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ HiFiBiO Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ HiFiBiO Therapeutics"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Pharmsynthez","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"HFB30132A","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ HiFiBiO","highestDevelopmentStatusID":"6","companyTruncated":"HiFiBiO Therapeutics \/ HiFiBiO"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Mirae Asset Financial Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Series D Financing","leadProduct":"HFB200301","moa":"Anti-TNFR2","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Mirae Asset Financial Group","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Mirae Asset Financial Group"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"HFB200301","moa":"TNFR2","graph1":"Oncology","graph2":"Phase I","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HiFiBiO Therapeutics \/ Novartis","highestDevelopmentStatusID":"6","companyTruncated":"HiFiBiO Therapeutics \/ Novartis"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"HFB200603","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Novartis","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Novartis"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"HFB200603","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"HFB200301","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HiFiBiO Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"HiFiBiO Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by HiFiBiO Therapeutics

    Menu

    HiFiBiO Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HFB200301,Tislelizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HiFiBiO Therapeutics Announces First Patient First Visit for the Evaluation of HFB200301 in Combination with T...

                            Details : HFB200301, a first-in-class agonistic anti-TNFR2 monoclonal antibody, in combination with tislelizumab, an investigational anti-PD-1 immune checkpoint inhibitor, for the treatment of advanced solid tumor.

                            Brand Name : HFB200301

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 23, 2023

                            Lead Product(s) : HFB200301,Tislelizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HFB200603,Tislelizumab

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603

                            Details : HFB200603 is a single-digit nanomolar binder to human and cynomolgus BTLA, capable of blocking BTLA interaction with its ligand HVEM, inducing the production of inflammatory cytokines in the tumor microenvironment of different human tumor types.

                            Brand Name : HFB200603

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 06, 2023

                            Lead Product(s) : HFB200603,Tislelizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HFB200603,Tislelizumab

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200603 in Combination with Tisle...

                            Details : Under the terms of the agreement, HiFiBiO Therapeutics will maintain control of the HFB200603 program, including global R&D and commercial rights. Novartis has agreed to supply tislelizumab for use in combination with HFB200603.

                            Brand Name : HFB200603

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 18, 2022

                            Lead Product(s) : HFB200603,Tislelizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HFB200301,Tislelizumab

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200301 in Combination with Tisle...

                            Details : Under the terms of the agreement, HiFiBiO Therapeutics will maintain control of the HFB200301 program, including global R&D and commercial rights. Novartis has agreed to supply tislelizumab for use in combination with HFB200301.

                            Brand Name : HFB200301

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 15, 2022

                            Lead Product(s) : HFB200301,Tislelizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HFB200301

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Mirae Asset Financial Group

                            Deal Size : $75.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline With Two Lead Immuno-Oncolog...

                            Details : HiFiBiO Therapeutics will use the proceeds from the financing to advance two lead antibody oncology assets into Phase I clinical trials - HFB200301, a novel anti-TNFR2 antibody and HFB301001, a differentiated second generation anti-OX-40 antibody.

                            Brand Name : HFB200301

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 14, 2021

                            Lead Product(s) : HFB200301

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Mirae Asset Financial Group

                            Deal Size : $75.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HFB30132A

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : Pharmsynthez

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            HiFiBiO, Pharmsynthez and IBCh Sign Covid-19 Antibody Development Deal

                            Details : The partnership aims to advance HFB30132A, a SARS-CoV-2 neutralizing antibody for the treatment of COVID-19, through clinical development and commercial sale in Russia, pending approval from the Ministry of Health of the Russian Federation.

                            Brand Name : HFB30132A

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 23, 2020

                            Lead Product(s) : HFB30132A

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : Pharmsynthez

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HFB30132A

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Recipient : ABL Bio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            HiFiBiO Therapeutics Announces a Global Strategic Partnership with ABL Bio for the Co-Development of a SARS-Co...

                            Details : Partnership with ABL Bio supports HiFiBiO Therapeutics' rapid clinical advancement of its SARS-CoV-2 neutralizing antibody, HFB30132A, for the treatment of COVID-19 patients.

                            Brand Name : HFB30132A

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 14, 2020

                            Lead Product(s) : HFB30132A

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Recipient : ABL Bio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Anti-AML specific antibodies

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Kite Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Kite and Hifibio Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia

                            Details : Through this collaboration, HiFiBiO will use its proprietary technology platforms to identify novel AML targets and anti-AML specific antibodies for Kite’s use in cell therapies.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 03, 2020

                            Lead Product(s) : Anti-AML specific antibodies

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Kite Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HFB30132A

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HiFiBiO Therapeutics Submits IND Application for Fully Human SARS-CoV-2 Neutralizing Antibody for the Treatmen...

                            Details : The highly differentiated antibody, HFB30132A, has been rapidly identified, engineered, and evaluated in multiple preclinical studies. A Phase I single-IV administration ascending dose study will assess the safety, tolerability, and pharmacokinetics of H...

                            Brand Name : HFB30132A

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 26, 2020

                            Lead Product(s) : HFB30132A

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            HiFiBiO Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mono & Bi-specific antibodies

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Coronavirus Immunotherapy Consortium

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            HiFiBiO Therapeutics Collaborates with Coronavirus Immunotherapy Consortium in the Fight Against COVID-19

                            Details : Company leverages its unprecedented antibody drug discovery and development engine empowered by proprietary single-cell profiling technology to identify, engineer, and evaluate multiple neutralizing antibodies against SARS-CoV-2.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 17, 2020

                            Lead Product(s) : Mono & Bi-specific antibodies

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Coronavirus Immunotherapy Consortium

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth